Table 2 Comparisons of maximum uTg with TgAb-negative
uTg ≥ 0.2 ng/ml (N = 39) | uTg < 0.2 ng/ml (N = 13) | t/χ2 | P | |
|---|---|---|---|---|
Age, yrs | 47.2 ± 14.1 | 39.2 ± 12.1 | − 1.827 | 0.074 |
Sex (male) | 15 | 3 | 0.453 | 0.501 |
BMI | 23.7 ± 3.9 | 22.5 ± 3.8 | − 0.938 | 0.353 |
NG | 16 | 6 | 0.105 | 0.746 |
HD | 5 | 1 | < 0.001 | 1.000 |
Hypertension | 4 | 2 | < 0.001 | 1.000 |
Diabetes | 2 | 1 | – | 1.000 |
Hyperthyroidism | 3 | 2 | 0.074 | 0.786 |
Tumor size (primary), mm | 21.7 ± 13.3 | 18.9 ± 10.4 | − 0.682 | 0.498 |
Multifocality (primary) | 4 | 5 | 3.628 | 0.057 |
Bilatrality (primary) | 4 | 2 | < 0.001 | 1.000 |
Surgical strategy | ||||
iCND | 2 | 1 | – | 1.000 |
bCND | 11 | 4 | – | 1.000 |
bCND + iLND | 20 | 8 | – | 0.403 |
bCND + bLND | 8 | 1 | – | 0.403 |
Harvested LNs | 32.7 ± 21.6 | 40.5 ± 19.7 | 1.148 | 0.256 |
Metastatic LNs | 9.6 ± 8.8 | 5.9 ± 7.3 | − 1.356 | 0.181 |
The ratio of metastatic LNs % | 34.1 ± 25.7 | 14.4 ± 10.5 | − 3.900 | 0.001* |
Diameter of recurrent LNs | 21.1 ± 14.7 | 14.6 ± 5.6 | − 2.279 | 0.027* |
≥ 25 mm | 13 | 0 | 5.778 | 0.023* |
Extranodal extension | 15 | 5 | < 0.001 | 1.000 |